Jennifer Angell

Effect of Oral Eliglustat on Splenomegaly in Patients With Gaucher Disease Type 1

Pramod K. Mistry, Elena Lukina, Hadhami Ben Turkia et al. · JAMA · 2015 · 156 citations

Medicine, Hematology, Pharmacotherapy +11

Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial

Timothy M. Cox, Guillermo Drelichman, Renata Cravo et al. · The Lancet · 2015 · 156 citations

Pharmacy, Internal Medicine, Pharmacotherapy +7

Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48‐month longitudinal cohort study

KB Sims, GM Pastores, NJ Weinreb et al. · Clinical Genetics · 2008 · 134 citations · Full text

Medicine, Pharmacotherapy, Bone Metabolism +16

Reproducibility of DXA absorptiometry: A model for bone loss estimates

Ghada El‐Hajj Fuleihan, Marcia A. Testa, Jennifer Angell et al. · Journal of Bone and Mineral Research · 1995 · 104 citations

Medicine, Biostatistics, Radiology +15

Imiglucerase (Cerezyme^®) improves quality of life in patients with skeletal manifestations of Gaucher disease

Neal J. Weinreb, J. A. Barranger, Seymour Packman et al. · Clinical Genetics · 2007 · 104 citations

Medicine, Internal Medicine, General Internal Medicine +15